KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) EBITDA: 2013-2024

Historic EBITDA for Palvella Therapeutics (PVLA) over the last 11 years, with Dec 2024 value amounting to -$3.4 million.

  • Palvella Therapeutics' EBITDA fell 108.87% to -$3.4 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$17.4 million, marking a year-over-year decrease of 197.30%. This contributed to the annual value of -$17.4 million for FY2024, which is 197.30% down from last year.
  • As of Q4 2024, Palvella Therapeutics' EBITDA stood at -$3.4 million, which was up 51.70% from -$7.0 million recorded in Q3 2024.
  • In the past 5 years, Palvella Therapeutics' EBITDA ranged from a high of $38.0 million in Q4 2023 and a low of -$16.2 million during Q3 2021.
  • In the last 3 years, Palvella Therapeutics' EBITDA had a median value of -$6.0 million in 2022 and averaged -$2.8 million.
  • As far as peak fluctuations go, Palvella Therapeutics' EBITDA slumped by 2,305.67% in 2020, and later skyrocketed by 527.47% in 2023.
  • Palvella Therapeutics' EBITDA (Quarterly) stood at -$13.9 million in 2020, then skyrocketed by 33.02% to -$9.3 million in 2021, then climbed by 4.71% to -$8.9 million in 2022, then surged by 527.47% to $38.0 million in 2023, then tumbled by 108.87% to -$3.4 million in 2024.
  • Its EBITDA stands at -$3.4 million for Q4 2024, versus -$7.0 million for Q3 2024 and -$4.4 million for Q2 2024.